Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05760560
  4. Details
NCT05760560 Clinical Trial

Incidence of Postoperative Residual Neuromuscular Blockade in the Era of Sugammadex

Postoperative Residual Curarization Clinical Trial

Official title:
Incidence of Postoperative Residual Neuromuscular Blockade in the Era of Sugammadex

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05760560
Other study ID # TOF-Sugammadex
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 15, 2023
Est. completion date August 31, 2024

Study information
Verified date April 2023
Source Seoul National University Hospital
Contact Chang-Hoon Koo
Phone +821085098841
Email vollock9@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is a prospective observational study. A total 52 patients will be included in this study. We will observe the incidence of postoperative residual neuromuscular blockade in patients receiving sugammadex.

Recruitment information / eligibility
Status Recruiting
Enrollment 52
Est. completion date August 31, 2024
Est. primary completion date August 31, 2023
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: - Patients undergoing elective surgery under general anesthesia. - American Society of Anesthesiologists grade 1, 2, or 3. - Aged >18 years Exclusion Criteria: - Refusal to participate in the study - Body Mass Index < 18.5 kg/m2 or > 35 kg/m2 - History of neuromuscular disease. - History of allergy to neuromuscular blockade - Scheduled to transfer to the intensive care unit

Study Design

Related Conditions & MeSH terms

  • Delayed Emergence from Anesthesia
  • Postoperative Residual Curarization

Intervention

Drug:
• Sugammadex
At the end of surgery, neuromucular blockade will be reversed with 2mg/kg or 4mg/kg sugammadex depending on the depth of neuromuscular blockade.

Locations
Country Name City State
Korea, Republic of Seoul National University Bundang Hospital Seongnam Gyeonggi-do

Sponsors (1)
Lead Sponsor Collaborator
Seoul National University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary Postoperative residual neuromuscular blockade TOF ratio < 0.9 On the arrival of PACU
See also
  Status Clinical Trial Phase
Completed NCT05003024 - Comparison of Train of Four, Tetanus 50 and 100 Hz Recovery After Rocuronium Block Reversed by Sugammadex N/A
Completed NCT03291184 - Postoperative Residual Paralysis After Cardiac Surgery N/A
Recruiting NCT00753389 - Muscle Relaxants and Post-Anesthesia Complications N/A
Completed NCT03804346 - Infantile - Postoperative Residual Curarization - Study
Completed NCT05066035 - Residual Paralysis and Reversal With Routine Neostigmine Versus Half-dose Sugammadex and Routine Neostigmine Phase 4
Completed NCT05224648 - Comparison of Train of Four, Tetanus 50 and 100 Hz Recovery After Rocuronium Block Reversed by Neostigmine N/A
Completed NCT03665805 - Postoperative Residual Curarization in 2018
Completed NCT01651572 - Comparison Between Cisatracurium and Rocuronium in Terms of Recovery of the Muscular Strength in the Postoperative Phase After Surgery and General Anaesthesia Phase 4
Completed NCT03219138 - Algorithm of Muscle Function Tests to Detect Residual Neuromuscular Blockade. N/A
Completed NCT02697929 - Sugammadex/Neostigmine and Liver Transplantation N/A
Recruiting NCT03923556 - Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery Phase 4
Not yet recruiting NCT03460509 - Reversal With Low Doses of Sugammadex in Patients Undergoing Non-cardiac Surgery Phase 4
Recruiting NCT05051371 - Postoperative Residual Curarization in Elderly Patients in Post-anesthesia Care Unit